NCT03184571 2025-09-25
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
BerGenBio ASA
Phase 2 Completed
Clinical Trials
4 trialsNCT03654833 2023-03-14
MiST
University of Leicester
Phase 2 Unknown
NCT03824080 2021-12-21
Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes
GWT-TUD GmbH
Phase 2 Completed
NCT03184558 2021-11-09
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
BerGenBio ASA
Phase 2 Terminated